conditional

Ethionamide or prothionamide may be included in the treatment of MDR/RR-TB patients on
longer regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used or if better
options to compose a regimen are not possible.

Imipenem–cilastatin or meropenem may be included in the treatment of MDR/RR-TB patients
on longer regimens.

Pyrazinamide may be included in the treatment of MDR/RR-TB patients on longer regimens.

Delamanid may be included in the treatment of MDR/RR-TB patients aged 3 years or more on
longer regimens.

Ethambutol may be included in the treatment of MDR/RR-TB patients on longer regimens.

In patients with confirmed rifampicin-susceptible, isoniazid-resistant tuberculosis, treatment with rifampicin, ethambutol, pyrazinamide and levofloxacin is recommended for a duration of 6 months.

Particulate respirators, within the framework
of a respiratory protection programme, are
recommended to reduce M. tuberculosis
transmission to health workers, persons
attending health care facilities or other persons
in settings with a high risk of transmission.

Ventilation systems (including natural, mixed-mode,
mechanical ventilation, and recirculated air through
high-efficiency particulate air [HEPA] filters) are
recommended to reduce M. tuberculosis transmission to
health workers, persons attending health care facilities or
other persons in settings with a high risk of transmission.

Upper-room germicidal ultraviolet (GUV)
systems are recommended to reduce
M. tuberculosis transmission to health
workers, persons attending health care
facilities or other persons in settings with a
high risk of transmission.

Respiratory separation / isolation of people
with presumed or demonstrated infectious TB
is recommended to reduce M. tuberculosis
transmission to health workers or other
persons attending health care facilities.